BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 15/08/2025

Biosimilar User Fee Act III Regulatory Science Program Interim Public Meeting; Public Meeting; Interim Report; Availability; Request for Comments

The FDA is hosting a public meeting to review progress on the Biosimilar User Fee Act III Regulatory Science Program and solicit input on future research priorities. The meeting aims to advance interchangeable product development and improve biosimilar product development efficiency.

Source: Federal Register — Food and Drug AdministrationOpen original release →